Sanofi

Sanofi is cementing its position as an immunology powerhouse by agreeing to acquire Blueprint Medicines Corp of the US and its soon-to-be blockbuster Ayvakit in a deal that could be worth up to $9.5bn

Sanofi’s hopes that itepekimab will follow Dupixent onto the list of approved drugs for chronic obstructive pulmonary disease (COPD) have been hit by a mixed set of results from a pair of late-stage t

England’s health technology assessment (HTA) institute, NICE, has recommended in favor of making Pfizer’s Hympavzi (marstacimab) available on the National Health Service for preventing severe hemophil

Contract manufacturing of biologics is one of the few weak points in the typically overwhelming advantage the US holds over Europe in bestowing the first approval for new drug products, a Pink Sheet